Fibrin-targeting immunotherapy in Alzheimer’s Disease

Katerina Akassoglou, PhD, University of California San Francisco, San Francisco, CA, discusses fibrin-targeting immunotherapy. Previous research has identified the blood coagulation factor fibrinogen as a cause of neuroinflammation in neurological disease. This research focused on developing a monoclonal antibody capable of targeting the inflammatory domain of fibrinogen, without interfering with its beneficial coagulation effects. Data from preliminary studies demonstrated that the immunotherapy was able to enter the central nervous system and bind to fibrin, blocking neurodegeneration and inflammatory pathways in Alzheimer’s disease (AD) mouse models. The group are currently moving this through to clinical development. Toxicology tests in two species, including non-human primates, have been completed and the antibody has been humanized for clinical use. Phase I clinical trials started in healthy volunteers in May 2023. This interview took place at the Alzheimer's Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.